Valproic acid for the treatment of social anxiety disorder

被引：57

作者：

Kinrys, G ^{[1
]}

Pollack, MH ^{[1
]}

Simon, NM ^{[1
]}

Worthington, JJ ^{[1
]}

Nardi, AE ^{[1
]}

Versiani, M ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | 2003年 / 18卷 / 03期

关键词：

anticonvulsants; anxiety disorders; social anxiety disorder; valproic acid;

D O I：

10.1097/01.yic.0000064261.66765.9f

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The aim of the study was to examine the efficacy of valproic acid in participants with social anxiety disorder. Following a 2-week single-blind, placebo run-in period, 17 participants were enrolled in a 12-week open flexible-dose trial of valproic acid (500-2500 mg). The primary outcome measures were the mean change from baseline in the Liebowitz Social Anxiety Scale (LSAS) total score and responder status [defined as a Clinical Global Impression of Improvement score (CGI-1) less than or equal to 2]. Social anxiety symptoms as measured by the LSAS and CGI-I scores significantly improved with treatment. The mean reduction in the LSAS was 21.3 points in the last visit carried forward analysis and 19.1 points for the completer analysis, with 41.1% and 46.6% participants, respectively, achieving responder status. The results from this open-label trial suggest the potential efficacy of valproic acid for the treatment of social anxiety disorder. Placebo-controlled trials are indicated to confirm these findings.

引用

页码：169 / 172

页数：4

共 29 条

[1] Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy [J].